PE20211804A1 - Compuestos que aumentan la actividad del proteosoma - Google Patents
Compuestos que aumentan la actividad del proteosomaInfo
- Publication number
- PE20211804A1 PE20211804A1 PE2020002159A PE2020002159A PE20211804A1 PE 20211804 A1 PE20211804 A1 PE 20211804A1 PE 2020002159 A PE2020002159 A PE 2020002159A PE 2020002159 A PE2020002159 A PE 2020002159A PE 20211804 A1 PE20211804 A1 PE 20211804A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- alkyl
- activity
- increase
- options
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690563P | 2018-06-27 | 2018-06-27 | |
| US201862690565P | 2018-06-27 | 2018-06-27 | |
| PCT/US2019/039600 WO2020006296A1 (en) | 2018-06-27 | 2019-06-27 | Proteasome activity enhancing compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211804A1 true PE20211804A1 (es) | 2021-09-14 |
Family
ID=67439356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020002159A PE20211804A1 (es) | 2018-06-27 | 2019-06-27 | Compuestos que aumentan la actividad del proteosoma |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11560385B2 (https=) |
| EP (1) | EP3814338A1 (https=) |
| JP (2) | JP7561632B2 (https=) |
| KR (1) | KR20210024588A (https=) |
| CN (1) | CN112585132B (https=) |
| AU (1) | AU2019295765B2 (https=) |
| BR (2) | BR112020026580A2 (https=) |
| CA (1) | CA3103954A1 (https=) |
| CL (1) | CL2020003380A1 (https=) |
| CR (1) | CR20200652A (https=) |
| IL (1) | IL279698A (https=) |
| MA (1) | MA53014A (https=) |
| MX (1) | MX2020014082A (https=) |
| PE (1) | PE20211804A1 (https=) |
| PH (1) | PH12020552261A1 (https=) |
| SG (1) | SG11202013026WA (https=) |
| WO (1) | WO2020006296A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102767739B1 (ko) | 2018-06-27 | 2025-02-12 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
| MX2021003904A (es) | 2018-10-05 | 2021-10-26 | Annapurna Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj. |
| CN111423353B (zh) * | 2020-04-29 | 2022-03-22 | 湖北省生物农药工程研究中心 | 多取代n-芳基吡咯类化合物及其制备方法 |
| CN112142642B (zh) * | 2020-10-15 | 2022-03-04 | 华侨大学 | 一种1,2,3-三取代-5-三氟甲基吡咯衍生物的制备方法 |
| WO2023107597A2 (en) * | 2021-12-08 | 2023-06-15 | Kineta, Inc. | Bicyclic heteroaromatic amide compounds and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1142508A (en) | 1966-04-27 | 1969-02-12 | Whitefin Holding Sa | Pyrrole derivatives |
| GB1154744A (en) | 1966-05-17 | 1969-06-11 | Whitefin Holding Sa | Disubstituted Aminoethanols |
| AP9801302A0 (en) | 1997-07-23 | 2000-01-23 | Pfizer | Indole compounds as anti-inflammatory/analgesic agents.. |
| BR9907228A (pt) | 1998-01-23 | 2000-10-24 | Nat Jewish Med & Res Center | Uso de uma proteìna de choque térmico, processo para proteger um mamìfero de uma doença, formulação para proteger um mamìfero de desenvolver uma doença, uso de uma molécula de ácido nucleico, e processo para prescrever um tratamento para hiper-sensibilidade das vias aéreas ou limitação do fluxo de ar associado com uma doença envolvendo resposta inflamatória |
| US7842470B2 (en) | 2001-10-09 | 2010-11-30 | Oregon Health & Science University | Method for pharmacoperones correction of GnRHR mutant protein misfolding |
| US20060148767A1 (en) | 2001-12-06 | 2006-07-06 | George Cioca | Use of acyl salicylates as heat shock inducers |
| CA2545433A1 (en) | 2003-11-12 | 2005-05-26 | Amicus Therapeutics Inc. | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| EP3782655A1 (en) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| AU2006254796B2 (en) | 2005-06-08 | 2012-08-16 | Amicus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
| US20070207992A1 (en) | 2006-02-21 | 2007-09-06 | Board Of Trustees Of Michigan State University | Geldanamycin derivatives and method of use thereof |
| WO2007131034A1 (en) | 2006-05-03 | 2007-11-15 | The Regents Of The University Of Michigan | Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70 |
| PL2533050T6 (pl) | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| PL1860101T3 (pl) | 2006-05-24 | 2011-10-31 | Amicus Therapeutics Inc | Sól winianu izofagominy i sposoby zastosowania |
| WO2007150064A2 (en) | 2006-06-23 | 2007-12-27 | Amicus Therapeutics, Inc. | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE |
| WO2008024978A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
| AU2009228765B2 (en) | 2008-03-24 | 2012-05-31 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| KR20120117905A (ko) * | 2010-01-28 | 2012-10-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 프로테아좀 활성을 향상시키는 조성물 및 방법 |
| HUE044867T2 (hu) | 2011-05-12 | 2019-11-28 | Proteostasis Therapeutics Inc | Proteosztázis szabályzók |
| US9849135B2 (en) * | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
| AU2014282886A1 (en) | 2013-06-17 | 2015-12-17 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
| FR3008977A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2015073528A1 (en) * | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
-
2019
- 2019-06-27 JP JP2020573524A patent/JP7561632B2/ja active Active
- 2019-06-27 AU AU2019295765A patent/AU2019295765B2/en not_active Ceased
- 2019-06-27 CR CR20200652A patent/CR20200652A/es unknown
- 2019-06-27 CN CN201980055152.2A patent/CN112585132B/zh active Active
- 2019-06-27 BR BR112020026580-2A patent/BR112020026580A2/pt unknown
- 2019-06-27 WO PCT/US2019/039600 patent/WO2020006296A1/en not_active Ceased
- 2019-06-27 CA CA3103954A patent/CA3103954A1/en active Pending
- 2019-06-27 KR KR1020217002233A patent/KR20210024588A/ko not_active Ceased
- 2019-06-27 MA MA053014A patent/MA53014A/fr unknown
- 2019-06-27 MX MX2020014082A patent/MX2020014082A/es unknown
- 2019-06-27 PE PE2020002159A patent/PE20211804A1/es unknown
- 2019-06-27 SG SG11202013026WA patent/SG11202013026WA/en unknown
- 2019-06-27 BR BR122023023216-0A patent/BR122023023216A2/pt unknown
- 2019-06-27 EP EP19744945.7A patent/EP3814338A1/en not_active Withdrawn
-
2020
- 2020-12-23 CL CL2020003380A patent/CL2020003380A1/es unknown
- 2020-12-23 US US17/133,372 patent/US11560385B2/en active Active
- 2020-12-23 IL IL279698A patent/IL279698A/en unknown
- 2020-12-23 PH PH12020552261A patent/PH12020552261A1/en unknown
-
2022
- 2022-11-18 US US18/057,020 patent/US12319698B2/en active Active
-
2024
- 2024-06-12 JP JP2024094936A patent/JP2024138260A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP7561632B2 (ja) | 2024-10-04 |
| IL279698A (en) | 2021-03-01 |
| SG11202013026WA (en) | 2021-01-28 |
| JP2024138260A (ja) | 2024-10-08 |
| CR20200652A (es) | 2021-04-28 |
| US12319698B2 (en) | 2025-06-03 |
| CA3103954A1 (en) | 2020-01-02 |
| AU2019295765A1 (en) | 2021-01-21 |
| WO2020006296A1 (en) | 2020-01-02 |
| JP2021529792A (ja) | 2021-11-04 |
| PH12020552261A1 (en) | 2021-08-02 |
| US20230183256A1 (en) | 2023-06-15 |
| KR20210024588A (ko) | 2021-03-05 |
| CL2020003380A1 (es) | 2021-05-14 |
| CN112585132B (zh) | 2025-02-28 |
| US20210115057A1 (en) | 2021-04-22 |
| CN112585132A (zh) | 2021-03-30 |
| EP3814338A1 (en) | 2021-05-05 |
| BR112020026580A2 (pt) | 2021-03-23 |
| US11560385B2 (en) | 2023-01-24 |
| AU2019295765B2 (en) | 2024-08-29 |
| MA53014A (fr) | 2021-05-05 |
| BR122023023216A2 (pt) | 2024-02-20 |
| MX2020014082A (es) | 2021-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211804A1 (es) | Compuestos que aumentan la actividad del proteosoma | |
| ECSP22046699A (es) | Inhibidores de kras g12c | |
| CO2019012271A2 (es) | Péptido activador de receptor de gip | |
| PE20180462A1 (es) | Moduladores cot y metodos de uso de los mismos | |
| CO2020012824A2 (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma | |
| DOP2018000268A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| PE20191461A1 (es) | Compuestos amida para el tratamiento del vih | |
| MX394380B (es) | Compuestos dinucleótidos cíclicos para eltratamiento de cáncer | |
| CO2019013823A2 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| UY36838A (es) | Compuestos heterocíclicos moduladores de la señalización de tnf alfa y composiciones farmacéuticas que los contienen | |
| DOP2015000261A (es) | Compuesto peptídico como activador de los receptores del glp-1 y del gip | |
| PE20180327A1 (es) | Proceso para preparar 4-amino-piridazinas | |
| EA201791094A1 (ru) | Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки | |
| CO2019005552A2 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos | |
| ECSP21040278A (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| ECSP21013743A (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| EA201790896A1 (ru) | Пролекарства фенольных агонистов trpv1 | |
| MX2019012505A (es) | Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso. | |
| DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| MX2018009408A (es) | Rapaglutinas, nuevos inhibidores de transportadores de glucosa (glut) y uso de los mismos. | |
| CL2018002023A1 (es) | Uso de moduladores de receptores de gabaa para el tratamiento de picor. | |
| CL2020002217A1 (es) | Uso de alcoxipirazoles como inhibidores de la nitrificación | |
| PE20190376A1 (es) | Combinaciones farmaceuticas para el tratamiento del cancer | |
| MX2024007360A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| CU20160148A7 (es) | Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2 |